KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Depreciation & Amortization (CF) (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $12.8 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Depreciation & Amortization (CF) fell 18.06% year-over-year to $12.8 million, compared with a TTM value of $70.5 million through Dec 2023, up 65.7%, and an annual FY2025 reading of $59.0 million, down 6.39% over the prior year.
  • Depreciation & Amortization (CF) was $12.8 million for Q4 2023 at Ginkgo Bioworks Holdings, down from $21.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $21.1 million in Q3 2023 and bottomed at $4.0 million in Q4 2020.
  • Average Depreciation & Amortization (CF) over 4 years is $11.2 million, with a median of $8.9 million recorded in 2022.
  • Peak annual rise in Depreciation & Amortization (CF) hit 136.18% in 2023, while the deepest fall reached 18.06% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $4.0 million in 2020, then surged by 99.88% to $8.0 million in 2021, then surged by 95.76% to $15.7 million in 2022, then dropped by 18.06% to $12.8 million in 2023.
  • Business Quant data shows Depreciation & Amortization (CF) for DNA at $12.8 million in Q4 2023, $21.1 million in Q3 2023, and $17.7 million in Q2 2023.